دورية أكاديمية
Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations.
| العنوان: | Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations. |
|---|---|
| المؤلفون: | Singh J; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA., Hatcher S; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA., Ku AA; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA., Ding Z; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA., Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA; Department of Radiation Oncology, University of California, San Francisco, California, USA; Department of Urology, University of California, San Francisco, California, USA., Sharma RA; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA; UCL Cancer Institute, University College London, London, UK., Pfister SX; Global Translational Science, Varian, a Siemens Healthineers company, Palo Alto, California, USA. Electronic address: sophia.pfister@varian.com. |
| المصدر: | Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2021 Nov; Vol. 33 (11), pp. 694-704. Date of Electronic Publication: 2021 Aug 31. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : London : W.B. Saunders Original Publication: [London, UK] : Springer International, [c1989- |
| مواضيع طبية MeSH: | Neoplasms*/drug therapy , Neoplasms*/radiotherapy , Pharmaceutical Preparations* , Radiation Oncology*, Combined Modality Therapy ; Humans |
| مستخلص: | Radiotherapy plays an essential role in the treatment of more than half of all patients with cancer. In recent decades, advances in devices that deliver radiation and the development of treatment planning software have helped radiotherapy attain precise tumour targeting with minimal toxicity to surrounding tissues. Simultaneously, as more targeted drug therapies are being brought into the market, there has been significant interest in improving cure rates for cancer by adding drugs to radiotherapy to widen the therapeutic window, the difference between normal tissue toxicity and treatment efficacy. The development of new combination therapies will require judicious adaptation of preclinical models that are routinely used for traditional drug discovery. Here we highlight the strengths and weaknesses of each of these preclinical models and discuss how they can be used optimally to identify new and clinically beneficial drug-radiotherapy combinations. (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: 3D tumor model; drug-radiotherapy combinations; high-throughput screen; in vivo; organoid; preclinical models; radiosensitizer; spheroid |
| المشرفين على المادة: | 0 (Pharmaceutical Preparations) |
| تواريخ الأحداث: | Date Created: 20210903 Date Completed: 20211125 Latest Revision: 20211125 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.clon.2021.08.008 |
| PMID: | 34474951 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1433-2981 |
|---|---|
| DOI: | 10.1016/j.clon.2021.08.008 |